Dexlansoprazole MR
Phase 3Small molecule
TakedaDexlansoprazole MR is one of 75 small molecule programs targeting Gastroesophageal Reflux Disease. It is currently in Phase 3.
2
Indications
14
Total Trials
0
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
80 competitors in Gastroesophageal Reflux Disease
#DrugCompanyPhaseTrials
1Protonix
WWyeth-Lederle Vaccines
Approved
Prevacid
TakedaPhase 3
Pamelor
SSpecgx
Approved
Rabeprazole ER
EisaiPhase 3
Zantac 150
CChattem
Phase 3
Pulmicort
SSalix
Phase 3
Esomeprazole Mg
AstraZenecaPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
DWP14012
Daewoong Pharmaceutical Co. LTD.Phase 3
Domperidone
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Esophagitis5 trials
Gastroesophageal Reflux Disease2 trials
Heartburn1 trial
4 more indications
Safety and Efficacy1 trial
Quality of Life1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexlansoprazole MR. EMBL-EBI & Wellcome Sanger Institute.
- [4]